Literature DB >> 23071187

Evolving epidemiology of pulmonary arterial hypertension.

Thenappan Thenappan, John J Ryan, Stephen L Archer.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23071187      PMCID： PMC3480514          DOI： 10.1164/rccm.201207-1266ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  21 in total

1.  Relation of mean pulmonary arterial wedge pressure and left ventricular end-diastolic pressure.

Authors:  E D Flores; R A Lange; L D Hillis
Journal:  Am J Cardiol       Date:  1990-12-15       Impact factor: 2.778

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  A USA-based registry for pulmonary arterial hypertension: 1982-2006.

Authors:  T Thenappan; S J Shah; S Rich; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2007-09-05       Impact factor: 16.671

4.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

5.  Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension.

Authors:  John J Ryan; Jonathan D Rich; Thejasvi Thiruvoipati; Rajiv Swamy; Gene H Kim; Stuart Rich
Journal:  Am Heart J       Date:  2012-04       Impact factor: 4.749

6.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

7.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

8.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

9.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Authors:  Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

10.  The WHO classification of pulmonary hypertension: A case-based imaging compendium.

Authors:  John J Ryan; Thenappan Thenappan; Nancy Luo; Thanh Ha; Amit R Patel; Stuart Rich; Stephen L Archer
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017
View more
  19 in total

Review 1.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

2.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.

Authors:  Hongyang Pi; Chad M Kosanovich; Adam Handen; Michael Tao; Jacqueline Visina; Gabrielle Vanspeybroeck; Marc A Simon; Michael G Risbano; Aken Desai; Michael A Mathier; Belinda N Rivera-Lebron; Quyen Nguyen; Jennifer Kliner; Mehdi Nouraie; Stephen Y Chan
Journal:  Chest       Date:  2020-02-25       Impact factor: 9.410

4.  Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension.

Authors:  Jason H Karnes; Howard W Wiener; Tae-Hwi Schwantes-An; Balaji Natarajan; Andrew J Sweatt; Abhishek Chaturvedi; Amit Arora; Ken Batai; Vineet Nair; Heidi E Steiner; Jason B Giles; Jeffrey Yu; Maryam Hosseini; Michael W Pauciulo; Katie A Lutz; Anna W Coleman; Jeremy Feldman; Rebecca Vanderpool; Haiyang Tang; Joe G N Garcia; Jason X-J Yuan; Rick Kittles; Vinicio de Jesus Perez; Roham T Zamanian; Franz Rischard; Hemant K Tiwari; William C Nichols; Raymond L Benza; Ankit A Desai
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

Review 5.  Mitochondrial dynamics in pulmonary arterial hypertension.

Authors:  John Ryan; Asish Dasgupta; Jessica Huston; Kuang-Huieh Chen; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2015-02-13       Impact factor: 4.599

6.  Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.

Authors:  Bradley A Maron; Ronald H Goldstein; Sharon I Rounds; Shelley Shapiro; Matthew Jankowich; Eric Garshick; Marilyn L Moy; David Gagnon; Gaurav Choudhary
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

7.  Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients.

Authors:  Bradley A Maron; Gaurav Choudhary; Umar A Khan; Matthew D Jankowich; Hope McChesney; Sarah J Ferrazzani; Sainath Gaddam; Satish Sharma; Alexander R Opotowsky; Deepak L Bhatt; Thomas P Rocco; Jayashri R Aragam
Journal:  Circ Heart Fail       Date:  2013-06-27       Impact factor: 8.790

8.  An elderly lady with Fever of unknown etiology and severe pulmonary hypertension: intravascular lymphoma-an elusive diagnosis.

Authors:  Nupur Sinha; Luis Lantigua; Masooma Niazi; Gilda Diaz-Fuentes
Journal:  Case Rep Med       Date:  2013-12-19

9.  MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.

Authors:  Lin Deng; Francisco J Blanco; Hannah Stevens; Ruifang Lu; Axelle Caudrillier; Martin McBride; John D McClure; Jenny Grant; Matthew Thomas; Maria Frid; Kurt Stenmark; Kevin White; Anita G Seto; Nicholas W Morrell; Angela C Bradshaw; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2015-08-26       Impact factor: 17.367

10.  Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR).

Authors:  Jeff Min; Rui Feng; David Badesch; Erika Berman-Rosenzweig; Charles Burger; Murali Chakinala; Teresa De Marco; Jeremy Feldman; Anna Hemnes; Evelyn M Horn; Matthew R Lammi; Stephen Mathai; John W McConnell; Kenneth Presberg; Jeffrey Robinson; Jeffrey Sager; Oksana A Shlobin; Marc Simon; Thenappan Thenappan; Corey Ventetuolo; Nadine Al-Naamani
Journal:  Ann Am Thorac Soc       Date:  2020-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.